Diverse effects: augmentation, inhibition, and non-efficacy of 12-O-tetradecanoylphorbol-13-acetate (TPA) on retrovirus genome expression in vivo and in vitro.

Important note: Information in this article was accurate in 1982. The state of the art may have changed since the publication date.

Diverse effects: augmentation, inhibition, and non-efficacy of 12-O-tetradecanoylphorbol-13-acetate (TPA) on retrovirus genome expression in vivo and in vitro.

Carcinogenesis. 1982;3(3):261-5. Unique Identifier : AIDSLINE MED/82208967
Lipp M; Scherer B; Lips G; Brandner G; Hunsmann G

Abstract: The action of 12-O-tetradecanoylphorbol-13-acetate (TPA) on several retrovirus-related functions was investigated in four virus-host cell systems. The following effects were recorded: (i) in STU-mice, infected with the Friend virus complex (Friend) murine leukaemia virus/Friend spleen focus forming virus) and treated with TPA (50 ng/g) for one week prior to infection, the number of spleen foci increased 5-fold over the control. (ii) Addition of TPA (0.04 to 40 ng/ml) to virus-producing cell systems resulted in a 2-fold increase of extracellular reverse transcriptase activity. The maximum response was observed in Friend leukemia virus-producing mouse cells at 0.1 to 0.4 ng TPA/ml and in simian sarcoma virus-producing rat cells at 4 ng/ml. (iii) The efficiency of transformation of BalbC 3T3 cells by Moloney murine sarcoma virus, tested in a focus formation assay, was slightly enhanced by TPA. (iv) TPA inhibited the induction of endogenous virus formation in B cell mitogen-stimulated spleen cell cultures from BalbC mice.

Keywords: Animal Cell Line Cell Transformation, Viral/DRUG EFFECTS Cocarcinogenesis Female Friend Virus/*DRUG EFFECTS/GENETICS Genes, Viral/DRUG EFFECTS Leukemia, Experimental/*METABOLISM Mice Mice, Inbred Strains Phorbols/*PHARMACOLOGY Polyomavirus macacae/GENETICS Rats Reverse Transcriptase/*BIOSYNTHESIS Sarcoma Viruses, Simian/DRUG EFFECTS/GENETICS Support, Non-U.S. Gov't Tetradecanoylphorbol Acetate/*PHARMACOLOGY Tumor Virus Infections/ENZYMOLOGY Virus Activation/DRUG EFFECTS JOURNAL ARTICLE

821030
M82A0012

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1982. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1982. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .